Giza also said earnings per share increased 44% , attributing the rise to earnings strength and the impact of an accelerated share buyback program. Net leverage improved to 2.5x , which she described as the bottom end of the company’s lowered target corridor, down from 3.4x at the end of 2022.Giza said the company closed 2025 with “strong results,” including organic revenue growth of 8% . She reported that reported operating income grew 31% and reported net income rose 82% , while operating income excluding ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker3Ladies and gentlemen, welcome to the report on the fourth quarter and financial year 2025 conference call. I'm Moritz, the conference call operator. I would like to remind you that all participants will be in a listen-only mode, and the conference is being recorded. The presentation will be followed by a question-and-answer session. You can register for questions at any time by pressing star and one on your telepho ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Company ParticipantsCarla Burigatto - EVP of Communications and Corporate AffairsHelen Giza - CEOMaria Rugamer - JournalistMartin Fischer - CFOPatricia Weiss - Senior CorrespondentNone - Company RepresentativeCarla BurigattoGood morning, and welcome to Fresenius Medical Care AG's annual press conference. My name is Carla Burigato, Executive Vice President, Communications and Corporate Affairs. I'm delighted to welcome you ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Company ParticipantsBritta Becks - Reporter and CorrespondentCarla Burigatto - EVP of Communications and Corporate AffairsHelen Giza - CEOMarcel Jan Dinkel - News ReporterMaria Rugamer - JournalistMartin Fischer - CFOPatricia Weiss - Senior CorrespondentSonja Wind - News ReporterCarla BurigattoGood morning, and welcome to Fresenius Medical Care AG's Annual Press Conference. My name is Carla Burigatto, Executive Vice Presid ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Speaker0Good morning, and welcome to Fresenius Medical Care AG's annual press conference. My name is Carla Burigato, Executive Vice President, Communications and Corporate Affairs. I'm delighted to welcome you today and appreciate all the journalists joining via live stream. Today's press conference is virtual and being streamed publicly as a webcast in both English and German. You can select your preferred language at the ...

Core Insights - The S&P 500 index experienced a rise as investors reacted to mixed signals from the Federal Reserve regarding interest rates and inflation [1] - The Federal Reserve maintained interest rates but showed divided opinions on future actions, with some officials open to rate hikes if inflation persists, while others may consider cuts if inflation eases [1] - Recent economic data showed unexpected cooling in inflation, strong job growth, and a decrease in unemployment, contributing to ongoing market volatility [2] Value Investing - Value investing focuses on acquiring stocks priced below their intrinsic value, allowing investors to buy low and potentially profit later [3] - A key metric for value investors is earnings yield, which indicates the profit a company generates per dollar of its stock price, calculated as (Annual Earnings per Share/Market Price) x 100 [4] - Earnings yield can be compared to bond returns, such as the 10-year Treasury yield, to assess the attractiveness of stocks relative to fixed-income securities [5] Screening Criteria - A primary screening criterion for stock selection is an earnings yield greater than 10%, supplemented by estimated EPS growth for the next 12 months that meets or exceeds the S&P 500 average [6] - Additional criteria include an average daily trading volume of at least 100,000 shares and a current stock price of $5 or higher [7][8] Selected Stocks - Five stocks that meet the screening criteria include DaVita (DVA), Ford (F), Centerra Gold (CGAU), Southwest Airlines (LUV), and Patria Investments Limited (PAX), all showing strong earnings growth estimates [9] - DaVita is projected to have earnings growth of 31% and 19% for 2026 and 2027, respectively, with recent EPS estimates increasing by $1.59 and $2.38 [10] - Ford's earnings are expected to grow by 40% and 19% in 2026 and 2027, with EPS estimates rising by $0.05 each over the past month [11] - Centerra Gold anticipates earnings growth of 45% and 57% for 2026 and 2027, with EPS estimates increasing by $0.05 and $0.17 [12] - Southwest Airlines forecasts significant earnings growth of 362% and 17% for 2026 and 2027, with recent EPS estimates up by $0.17 and $0.08 [13] - Patria Investments expects earnings growth of 25% and 17% for 2026 and 2027, with EPS estimates rising by $0.04 and $0.07 [14]

Last year was a forgettable one for DaVita (NYSE: DVA) shareholders, but understandably so. The stock ended up losing 25% of its value in calendar 2025 due to a combination of a declining number of dialysis patients, subpar guidance for most of the year, uncertainty as to how much insurers were willing to continue reimbursing the company, and an embarrassing ransomware attack reported in April. It's just possible, however, that the sellers overshot their target. As of 12:16 p.m. ET Tuesday, DaVita stock ...

Key Takeaways DVA posted Q4 adjusted EPS of $3.40 and revenue of $3.62 billion, both beating the Zacks Consensus Estimate.DaVita expanded gross margin by 98 bps to 33.4% and lifted adjusted operating margin to 20.4% in Q4.DVA issued 2026 adjusted EPS guidance of $13.60 to $15.00 and expects RPT growth of 1% to 2%.DaVita Inc. (DVA) delivered adjusted earnings per share (EPS) from continuing operations of $3.40 in the fourth quarter of 2025, up 51.8% year over year. The figure surpassed the Zacks Consensus Es ...

分组1: Pterodine - Pterodine reported better-than-expected quarterly results, with adjusted EPS at $1.80 and revenue at $1.08 billion, surpassing street expectations [2][4] - The company experienced its first billion-dollar quarter since 2021, indicating a significant cyclical structural rebound [4] - Guidance for Q1 revenue is projected between $1.15 billion and $1.4 billion, with EPS guidance between $1.89 and $2.25, both exceeding market expectations [5][4] - Pterodine is recognized as a core player in the AI sector, benefiting from increased demand for AI-related chips across various applications [3][6] 分组2: Dvita - Dvita's quarterly results showed strong performance with adjusted EPS of $3.40 and revenue of $3.62 billion, both exceeding street forecasts [8][9] - The company anticipates a bullish outlook for 2026, with adjusted EPS guidance between $13.60 and $15.00, reflecting confidence in reimbursement trends and operational momentum [8][9] - Dvita's results were supported by steady demand for kidney dialysis services and improved reimbursement rates, although they are still addressing operational challenges from a ransomware attack [9][10] 分组3: Pepsi - Pepsi reported adjusted EPS of $2.26 and revenue of $29.34 billion, both beating market expectations [12] - The company is experiencing volume softness in North America, with global food volume declining by 2%, while beverage volume increased by 1% [12][13] - Pepsi is implementing a pricing strategy shift, including planned price cuts, and expanding into protein-based snacks and functional drinks to meet changing consumer demands [13][14]

Financial Data and Key Metrics Changes - Fourth quarter adjusted operating income was $586 million, bringing full-year adjusted operating income to $2.094 billion [18] - Adjusted earnings per share from continuing operations for the fourth quarter was $3.40, with full-year adjusted EPS from continuing operations of $10.78 [18] - Free cash flow was $309 million in the fourth quarter, totaling just over $1 billion for the full year [18] Business Line Data and Key Metrics Changes - U.S. dialysis treatments declined by 1.1% for the full year compared to 2024, with a slight decline of about 20 basis points in the fourth quarter [19] - Revenue per treatment (RPT) grew approximately $12 sequentially in the fourth quarter, with full-year RPT at approximately $410, reflecting a 4.7% increase [20] - International adjusted operating income was $21 million for the fourth quarter, totaling $114 million for the full year, indicating strong performance and positive organic growth [21] Market Data and Key Metrics Changes - The company anticipates treatment volume for U.S. dialysis to be approximately flat in 2026, with a forecasted growth of 1%-2% in RPT [26] - The expiration of enhanced premium tax credits is expected to create a $40 million headwind in 2026, offset by the elimination of a $45 million headwind from the previous year's cyber incident [26] Company Strategy and Development Direction - The company is focused on enhancing patient care through clinical initiatives, including vaccination programs and partnerships with home care providers [14][15] - A strategic clinical partnership with Elara Caring aims to lower hospitalizations and missed treatment rates while improving patient experience [14] - The company expects to deliver an incremental $20 million of IKC operating income growth in 2026, building on its first profitable year in IKC [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining profit growth despite near-term financial headwinds, emphasizing a focus on clinical excellence [12][13] - The company expects adjusted operating income for 2026 to be in the range of $2.085 billion to $2.235 billion, reflecting a 3.2% growth at the midpoint [17] - Management highlighted the importance of addressing mortality rates and missed treatments to achieve long-term growth targets [32] Other Important Information - The company repurchased nearly 13 million shares for approximately $1.8 billion in 2025, with a leverage ratio of 3.26x consolidated EBITDA [22] - The midpoint of the guidance for 2026 adjusted EPS is $14.30, representing a 33% increase over the previous year [29] Q&A Session Summary Question: Confidence in returning to 2%+ volume growth - Management indicated that achieving this growth is tied to clinical improvements and expects benefits to materialize over the next two years [32] Question: Trends in missed treatments and mortality - Missed treatments were up in Q4, but year-over-year changes were minimal, with a noted correlation between missed treatments and mortality [41] Question: ACA headwind expectations - The company anticipates a $40 million headwind from ACA changes in 2026, with open enrollment performing better than expected [45] Question: Impact of cyber incident on financials - The cyber incident created a $70 million headwind in 2025, which is expected to be offset by the ACA headwind in 2026 [54] Question: IKC performance and future growth - Management noted that shared savings contributed to better-than-expected performance in IKC, with confidence in continued growth [56] Question: International business growth - The international segment is expected to grow through a mix of M&A and organic growth, with improving margins [67]